Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Collplant Holdings ( (CLGN) ) just unveiled an announcement.
CollPlant Biotechnologies reported its third-quarter financial results for 2025, highlighting significant advancements and strategic initiatives. The company announced the expansion of its rhCollagen and BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance its market presence. Recent developments include a collaboration with Mayo Clinic to create a humanized bioprinted skin model, and a comparative study showing its bioink, Collink.3D™, outperformed a leading extracellular matrix in tissue formation. Additionally, CollPlant is implementing cost-reduction measures and prioritizing its collaboration with AbbVie and the development of its dermal filler product. The company is also expanding its international distribution network for its tendon-repair product, Vergenix™ STR, into new markets.
The most recent analyst rating on (CLGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
Collplant Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by significant revenue and cash flow declines and negative profit margins. Technical analysis also indicates a bearish trend, while valuation metrics highlight the company’s unprofitability. These factors collectively suggest a high-risk investment without immediate signs of improvement.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is a company operating in the regenerative and aesthetics medicine industry, focusing on developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue regeneration and medical aesthetics.
Average Trading Volume: 96,038
Technical Sentiment Signal: Strong Sell
Current Market Cap: $28.23M
Learn more about CLGN stock on TipRanks’ Stock Analysis page.